Skip to Content

Host Immune Signatures as Predictors for Immunotherapy Regimens in Patients with Metastatic Renal Cell Carcinoma

In his study presented at the ONCLIVE National Fellows Forum for genitourinary cancers, Marc Machaalani examined how host immune signatures can be used as predictors for immunotherapy regimens in metastatic renal cell carcinoma (RCC) patients, which he elaborates on in this MEDtalk.

Marc Machaalani

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top